Sanofi Reports Increased Earnings Due to Beyfortus and Prior Vaccine Sales Performance

Sanofi Reports Increased Earnings Due to Beyfortus and Prior Vaccine Sales Performance

Sanofi Reports Increased Earnings Due to Beyfortus and Prior Vaccine Sales Performance

Sanofi has announced a noteworthy 25% increase in sales for its vaccine segment in the third quarter, bolstered by earlier-than-expected orders for flu vaccines, as well as rising income from Beyfortus, its RSV antibody designed for infants.

In its earnings release on Friday, the French-based pharmaceutical firm reported that sales for Beyfortus amounted to 645 million euros, which equates to roughly 0 million. The overall revenue from the vaccines division reached about 3.8 billion euros, contributing to total company revenues of .4 billion.

This performance surpassed Wall Street’s predictions, resulting in a rise in the company’s stock prices during Friday trading on both French and U.S. exchanges.

“We achieved nearly 16% sales growth in the third quarter, highlighting the fundamental strength of our product lineup,” stated Sanofi CEO Paul Hudson in a press release. He noted that the timing of flu vaccine demand and Beyfortus contributed significantly to this performance.

Beyfortus has received approval in the U.S. to aid in preventing respiratory syncytial virus infections among infants aged up to 24 months who are embarking on their first RSV season or who are still at risk in their second season. This antibody therapy was cleared last summer.

Sanofi, in conjunction with partner AstraZeneca, has recently secured regulatory nods for a new manufacturing line aimed at increasing the production of Beyfortus. The companies encountered challenges in meeting demand during Beyfortus’ inaugural season, which led to a scarcity of the 100 milligram doses for infants over 11 pounds. To manage this shortfall, the Centers for Disease Control and Prevention recommended prioritizing doses for high-risk infants and advised pregnant women to consider Pfizer’s RSV vaccine, Abrysvo, if suitable.

Sanofi anticipates that the enhanced capacity for Beyfortus will ensure access to the medication for all qualified infants in the United States.

The only alternative treatment for RSV prevention for infants is the antibody Synagis, which is prescribed exclusively for certain high-risk infants. Merck & Co. is also expected to introduce another competing antibody called clesrovimab, which they aim to launch for the 2025-2026 RSV season, contingent upon approval.

The typical RSV season in the U.S. generally commences in the fall and continues through winter.